INT99390

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2001
Last Reported 2010
Negated 2
Speculated 2
Reported most in Abstract
Documents 4
Total Number 6
Disease Relevance 3.12
Pain Relevance 0.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Ctnnb1) enzyme binding (Ctnnb1) DNA binding (Ctnnb1)
protein complex (Ctnnb1) cytoplasm (Ctnnb1) cell proliferation (Ctnnb1)
Anatomy Link Frequency
facial nerve 1
Ctnnb1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Glutamate 3 100.00 Very High Very High Very High
Peripheral nervous system 1 98.68 Very High Very High Very High
Inflammation 19 90.80 High High
cINOD 5 87.60 High High
antidepressant 2 86.00 High High
Hippocampus 22 67.76 Quite High
dexamethasone 7 57.24 Quite High
tetrodotoxin 1 25.00 Low Low
Action potential 1 25.00 Low Low
cytokine 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colorectal Cancer 10 99.16 Very High Very High Very High
Cancer 10 98.94 Very High Very High Very High
Apoptosis 24 98.08 Very High Very High Very High
INFLAMMATION 31 95.24 Very High Very High Very High
Colon Cancer 2 88.80 High High
Neurodegenerative Disease 10 82.36 Quite High
Pneumococcal Meningitis 21 69.04 Quite High
Infection 60 68.80 Quite High
Disease 33 62.52 Quite High
Death 4 42.20 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have examined beta-catenin as a potential target for these agents in colorectal cancer.
Spec (examined) Regulation (target) of beta-catenin associated with colorectal cancer
1) Confidence 0.62 Published 2001 Journal Dig. Dis. Sci. Section Abstract Doc Link 11713928 Disease Relevance 1.16 Pain Relevance 0
In tumors from treatment groups, the cytoplasmic staining for beta-catenin was unchanged; however, nuclear staining was absent except in the celecoxib group, where it was reduced to a median of 14%.
Neg (unchanged) Regulation (unchanged) of beta-catenin associated with cancer
2) Confidence 0.45 Published 2001 Journal Dig. Dis. Sci. Section Abstract Doc Link 11713928 Disease Relevance 1.13 Pain Relevance 0.09
However, in the azoxymethane-treated rat, where beta-catenin is frequently rendered GSK-3beta-insensitive, nabumetone failed to alter beta-catenin levels but did decrease beta-catenin nuclear localization and transcriptional activity as gauged by cyclin D1.
Neg (failed) Regulation (alter) of beta-catenin
3) Confidence 0.21 Published 2005 Journal Cancer Lett. Section Abstract Doc Link 15617833 Disease Relevance 0.24 Pain Relevance 0.12
We report that nabumetone decreased uninvolved intestinal mucosal beta-catenin levels in the MIN mouse with a concomitant increase in glycogen synthase kinase (GSK)-3beta levels, an enzyme that targets beta-catenin for destruction.
Regulation (targets) of beta-catenin
4) Confidence 0.21 Published 2005 Journal Cancer Lett. Section Abstract Doc Link 15617833 Disease Relevance 0.25 Pain Relevance 0.12
We investigated in the rat the effect of axotomy on the different subunits of excitatory glutamatergic AMPA (GLuR1-4), NMDA (NR1, NR2A-D) receptors, post-synaptic density 95, vesicular glutamate transporter 2, beta catenin and cadherin. mRNA levels and/or protein production were analyzed 1, 3, 8, 30 and 60 days after facial nerve axotomy by in situ hybridization and immunohistofluorescence. mRNAs coding for the GLuR2-4, NR1, NR2A, B, D subunits of glutamatergic receptors and for post-synaptic density 95, were less abundant after axotomy.
Spec (investigated) Regulation (effect) of beta catenin in facial nerve associated with glutamate
5) Confidence 0.16 Published 2005 Journal Neuroscience Section Abstract Doc Link 16182453 Disease Relevance 0 Pain Relevance 0.14
and an up-regulation of beta-catenin.
Regulation (regulation) of beta-catenin
6) Confidence 0.05 Published 2010 Journal BMC Infect Dis Section Body Doc Link PMC2915993 Disease Relevance 0.33 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox